



BioLineRx to Present at Biotech Showcase 2015 Conference in San Francisco

January 6, 2015 12:01 PM IST

JERUSALEM--(BUSINESS WIRE)--Jan. 6, 2015-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the Biotech Showcase 2015 Conference being held at the Parc 55 Wyndham Union Square Hotel in San Francisco, CA.

The BioLineRx presentation is scheduled to start at 11:30 a.m. PST (2:30 p.m. EST) on Tuesday, January 13, 2015. A live audio webcast of the presentation will be available online at [BioLineRx's investor web page](#). An archive of the event will also be available for those unable to listen live. Company management will be available to participate in one-on-one meetings with investors who are registered to attend the conference. Meetings may also be scheduled outside of Biotech Showcase by contacting BioLineRx's investor relations.

About BioLineRx

BioLineRx is a publicly-traded, clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Bellerophon BCM (*f/k/a* Ikaria) and is in the midst of a pivotal CE-Mark registration trial; BL-8040, a cancer therapy platform, which is in the midst of a Phase 2 study for acute myeloid leukemia (AML) as well as a Phase 1 study for stem cell mobilization; and BL-7010 for celiac disease, which has completed a Phase 1/2 study.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.



Source: BioLineRx

for BioLineRx
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D.
+1-212-375-2664
jdrumm@tiberend.com
or
Andrew Mielach
+1-212-375-2694
amielach@tiberend.com
or
Tsipi Haitovsky
Public Relations
+972-3-6240871
tsipihai5@gmail.com